Helen Milton

General Counsel at VIRIDIAN THERAPEUTICS, INC.

Health Technology

Consumer Services

Profile

Helen Milton is currently the Senior Vice President-Regulatory Affairs at Viridian Therapeutics, Inc. She previously worked as the Vice President-Global Regulatory Affairs & Quality at Keryx Biopharmaceuticals, Inc. from 2014 to 2017.
In 2020, she held the position of Senior VP-Regulatory Affairs & Quality at AMAG Pharmaceuticals, Inc. From 2021 to 2022, she worked as the Senior VP-Regulatory Affairs & Pharmacovigilance at Mallinckrodt Pharmaceuticals.
Dr. Milton obtained her undergraduate and doctorate degrees from The University of Liverpool.

Helen Milton active positions

Companies	Position	Start
VIRIDIAN THERAPEUTICS, INC.	General Counsel	31/12/2022

All active positions of Helen Milton

Former positions of Helen Milton

Companies	Position	End
AMAG PHARMACEUTICALS, INC.	General Counsel	30/11/2020
KERYX BIOPHARMACEUTICALS	General Counsel	30/04/2017

See the detail of Helen Milton's experience

Training of Helen Milton

The University of Liverpool

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Helen Milton's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
VIRIDIAN THERAPEUTICS, INC.	Health Technology

Private companies	2
Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA.	Health Technology
AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.	Health Technology

Private companies